Status:

COMPLETED

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

Lead Sponsor:

Oregon Aesthetic Technologies

Conditions:

Acne

Eligibility:

All Genders

15+ years

Phase:

NA

Brief Summary

This study will determine if the use of the BEAM device reduces the signs and symptoms of mild-to-moderate acne.

Eligibility Criteria

Inclusion

  • Age 15 years or older of either gender and of any racial/ethnic group.
  • At least 8 acne inflammatory lesions (see section 9) in the treatment and control areas.
  • Presence of clinically-evident facial acne of mild-to-moderate severity (score 2-4 on the Global Acne Severity Scale, see below)
  • Subjects must be in generally good health.
  • Subjects must be able and willing to comply with the requirements of the protocol.

Exclusion

  • Oral retinoid use within six months of entry into the study.
  • Systemic acne therapies (oral antibiotics) within 2 weeks of entry into the study.
  • Topical acne therapies (retinoids, antibiotics) within 1 week of entry into the study.
  • Microdermabrasion or superficial chemical peels at the site to be treated within 2 months of entry into the study.
  • Subjects with a history of dermabrasion or laser resurfacing at the site to be treated.
  • Use of topical lipid absorbing substances (Clinac AC) within 1 week of entry into the study.
  • Non-compliant subjects.
  • Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.
  • Subjects using alcohol-based topical solutions or "exfoliating" agents within 1 week of entry into the study.
  • Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
  • Pregnant or nursing females.
  • Subjects with known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
  • Subjects who have a history of significant post-inflammatory hyperpigmentation at the sites of acne lesions.

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2010

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT01162837

Start Date

June 1 2010

End Date

October 1 2010

Last Update

May 3 2012

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Baumann Cosmetic & Research Institute

Miami Beach, Florida, United States, 33140

2

Grekin Skin Institute

Warren, Michigan, United States, 48088

3

Oregon Dermatology & Research Institute

Portland, Oregon, United States, 97210